Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Vertex Pharmaceuticals Incorporated”

980 pharma patents match "Vertex Pharmaceuticals Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 980
Index total 30,257
Page 2 / 41

Quick answer

This filtered view shows 980 pharmaceutical patents matching "Vertex Pharmaceuticals Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

980 results for “Vertex Pharmaceuticals Incorporated” · 30,257 patents in full index Clear search

  1. US 12187698

    Crystalline forms of C21H22Cl2N4O2

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  2. US 12173324

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  3. US 12173337

    Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  4. US 12168009

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  5. US 12161674

    CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  6. US 12134767

    Materials and methods for treatment of hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  7. US 12129471

    Materials and methods for treatment of human genetic diseases including hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  8. US 12121524

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  9. US 12116606

    Complement factor I-related compositions and methods

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  10. US 12116343

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  11. US 12084438

    GCN2 inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  12. US 12065432

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

    Vertex Pharmaceuticals Incorporated · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  13. US 12060346

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  14. US 12053531

    Materials and methods for treatment of Duchenne Muscular Dystrophy

    Vertex Pharmaceuticals Incorporated · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  15. US 12049645

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  16. US 12043843

    Materials and methods for treatment of hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  17. US 12031150

    Methods, compositions and kits for increasing genome editing efficiency

    Vertex Pharmaceuticals Incorporated · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  18. US 12005127

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  19. US 12006516

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  20. US 11999971

    Stem cell derived islet differentiation

    Vertex Pharmaceuticals Incorporated · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  21. US 11992506

    Stem cell derived pancreatic islet differentiation

    Vertex Pharmaceuticals Incorporated · Granted May 28, 2024 · Expires May 23, 2044

    granted
  22. US 11980633

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted May 14, 2024 · Expires May 9, 2044

    granted
  23. US 11951206

    Cell housing device

    Vertex Pharmaceuticals Incorporated · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  24. US 11951212

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Vertex Pharmaceuticals Incorporated · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted